Related references
Note: Only part of the references are listed.Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Senthamil R. Selvan et al.
CURRENT CANCER DRUG TARGETS (2016)
Chemotherapy and immunotherapy: mapping the road ahead
Alistair M. Cook et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Rationale for combining immunotherapy with chemotherapy
Angus G. Dalgleish
IMMUNOTHERAPY (2015)
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia
Ilaria Iacobucci et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer
Maria Leticia Baptista Salvadori et al.
MEDICAL ONCOLOGY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Yong Wha Moon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
George C. Prendergast et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Minghui Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Paclitaxel and immune system
Aqeel Javeed et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2,3-dioxygenase
L. Ferdinande et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2008)
Reversing tumor immune suppression with intratumoral IL-12:: Activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors
Mehmet O. Kilinc et al.
JOURNAL OF IMMUNOLOGY (2006)
Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism
O Takikawa
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Share Paper
